|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000184730 |
Summary for APOBR |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000184730 | Gene symbol | APOBR |
| Gene name | apolipoprotein B receptor | |
| HGNC | 24087 | |
| Entrez ID | 55911 | |
| Gene type | protein_coding | |
| Synonyms | APOBR|APOB48R|APOB100R | |
| UniProtAcc | Q0VD83 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000184730 | APOBR | DB01593 | Zinc | SmallMoleculeDrug |
| ENSG00000184730 | APOBR | DB09130 | Copper | SmallMoleculeDrug |
| ENSG00000184730 | APOBR | DB14487 | Zinc acetate | SmallMoleculeDrug |
| ENSG00000184730 | APOBR | DB14533 | Zinc chloride | SmallMoleculeDrug |
| ENSG00000184730 | APOBR | DB14548 | Zinc sulfate, unspecified form | SmallMoleculeDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for APOBR |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| APOBR | 4.97e+02 | 1.08e+00 | 2.88e-01 | 3.77e+00 | 1.63e-04 | 5.47e-04 | THCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| APOBR | 1.04e+03 | 1.42e+00 | 1.24e-01 | 1.15e+01 | 1.84e-30 | 9.48e-30 | BRCA |
| APOBR | 1.94e+03 | -1.01e+00 | 4.34e-01 | -2.32e+00 | 2.02e-02 | 4.47e-02 | READ |
Top |
Sex-biased somatic mutation for APOBR |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for APOBR |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg16332159 | chr16:28494638 | CGI:chr16:28491492-28492170 | promoter | 6.38e-01 | 7.58e-01 | -2.56e+00 | 1.04e-02 | 2.71e-02 | -1.20e-01 |
| SARC | cg02042997 | chr16:28494565 | CGI:chr16:28491492-28492170 | promoter | 6.24e-01 | 5.04e-01 | 4.40e+00 | 1.06e-05 | 6.63e-05 | 1.20e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg02042997 | chr16:28494565 | CGI:chr16:28491492-28492170 | promoter | 6.05e-01 | 7.79e-01 | -6.22e+00 | 4.83e-10 | 7.16e-09 | -1.74e-01 |
| KIRC | cg16332159 | chr16:28494638 | CGI:chr16:28491492-28492170 | promoter | 6.02e-01 | 7.33e-01 | -5.59e+00 | 2.32e-08 | 1.45e-07 | -1.31e-01 |
| LUSC | cg08923160 | chr16:28494166 | CGI:chr16:28491492-28492170 | promoter | 6.29e-01 | 7.46e-01 | -2.25e+00 | 2.44e-02 | 2.79e-02 | -1.17e-01 |
| BLCA | cg03300649 | chr16:28493628 | CGI:chr16:28491492-28492170 | promoter | 6.72e-01 | 7.97e-01 | -3.50e+00 | 4.65e-04 | 1.25e-03 | -1.26e-01 |
| BLCA | cg08923160 | chr16:28494166 | CGI:chr16:28491492-28492170 | promoter | 5.71e-01 | 7.21e-01 | -2.24e+00 | 2.53e-02 | 2.94e-02 | -1.50e-01 |
| LIHC | cg08923160 | chr16:28494166 | CGI:chr16:28491492-28492170 | promoter | 6.33e-01 | 7.50e-01 | -3.54e+00 | 3.96e-04 | 6.96e-04 | -1.17e-01 |
| ESCA | cg08923160 | chr16:28494166 | CGI:chr16:28491492-28492170 | promoter | 5.88e-01 | 7.56e-01 | -2.79e+00 | 5.28e-03 | 3.44e-02 | -1.69e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg08923160 | chr16:28494166 | CGI:chr16:28491492-28492170 | promoter | 6.47e-01 | 7.71e-01 | -2.26e+00 | 2.35e-02 | 2.90e-02 | -1.23e-01 |
| BLCA | cg07337290 | chr16:28493999 | CGI:chr16:28491492-28492170 | promoter | 4.75e-01 | 3.65e-01 | 2.01e+00 | 4.46e-02 | 4.61e-02 | 1.10e-01 |
Top |
Exon skipping events with PSI in TCGA for APOBR |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for APOBR |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for APOBR |
| TFs related to APOBR. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CHOL | GABPA | APOBR | 3.00e+00 | 2.43e-03 | 4.28e+00 | 9.90e-01 | Female-biased |
| LAML | SPIB | APOBR | 3.11e+00 | 4.80e-03 | 4.19e+00 | 9.82e-01 | Female-biased |
| APOBR related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for APOBR |
| RBPs related to ES in APOBR. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | hnRNPK | exon_skip_135033 | 9.20e+00 | 9.83e-01 | 8.88e+00 | 1.33e-02 | Male-biased |
| APOBR related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs9925335 | chr16:23336560:C:T | - | 0.159692338895447 | 0.022324089551848 | KIRP | Female-baised eQTL |
| rs1559457 | chr16:26289201:G:A | - | -0.0698696741277389 | 0.0266930562844774 | COAD | Female-baised eQTL |
| rs11074765 | chr16:26289877:A:G | - | -0.0654585247553853 | 0.0428452352012912 | COAD | Female-baised eQTL |
| rs7196877 | chr16:26291193:C:G | - | -0.0649686695818939 | 0.0466796782935897 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7202093 | chr16:28987628:C:T | - | 0.152609113881293 | 1.51528716896953e-06 | BLCA | Male-baised eQTL |
| rs112600506 | chr16:28993042:A:G | - | 0.140401741871369 | 0.000166477235677961 | BLCA | Male-baised eQTL |
| rs73535859 | chr16:28987287:C:T | - | 0.137958062126488 | 0.000186539763168083 | BLCA | Male-baised eQTL |
| rs7193414 | chr16:28994574:T:C | - | 0.141551251482137 | 0.000192624635650513 | BLCA | Male-baised eQTL |
| rs61587226 | chr16:28953352:C:T | - | 0.145546955996388 | 0.000328990215994166 | BLCA | Male-baised eQTL |
| rs8047616 | chr16:28956367:C:T | - | 0.145546955996388 | 0.000328990215994166 | BLCA | Male-baised eQTL |
| rs60603404 | chr16:28958196:T:A | - | 0.145546955996388 | 0.000328990215994166 | BLCA | Male-baised eQTL |
| rs8044724 | chr16:28977491:G:A | - | 0.145607680619072 | 0.000330133234431749 | BLCA | Male-baised eQTL |
| rs11863981 | chr16:28973283:G:C | - | 0.145206954634993 | 0.000356352303032314 | BLCA | Male-baised eQTL |
| rs61747536 | chr16:28982048:C:T | - | 0.144311255947285 | 0.000404615186222632 | BLCA | Male-baised eQTL |
| rs7184156 | chr16:28975676:G:A | - | 0.138630251273665 | 0.000738582307690685 | BLCA | Male-baised eQTL |
| rs8060015 | chr16:28970906:A:G | - | 0.138531845406823 | 0.000745470547247879 | BLCA | Male-baised eQTL |
| rs113677814 | chr16:28961777:A:G | - | 0.135475706358892 | 0.000804964506959069 | BLCA | Male-baised eQTL |
| rs8044999 | chr16:28963337:A:G | - | 0.135431682670919 | 0.000808172037586045 | BLCA | Male-baised eQTL |
| rs179214 | chr16:19298301:A:G | - | 0.0815336094450711 | 0.00880045707707241 | BLCA | Male-baised eQTL |
| rs4787320 | chr16:25406948:A:G | - | -0.054534566391908 | 0.0148241724521426 | BLCA | Male-baised eQTL |
| rs7200364 | chr16:25413004:T:A | - | -0.0544254106379227 | 0.016689864071705 | BLCA | Male-baised eQTL |
| rs9931782 | chr16:25368772:C:T | - | -0.0574154794784064 | 0.0184222203243614 | BLCA | Male-baised eQTL |
| rs9931891 | chr16:25369001:A:C | - | -0.0568493108475504 | 0.02078416475113 | BLCA | Male-baised eQTL |
| rs7203160 | chr16:25371128:T:C | - | -0.0545909585410783 | 0.0283432539468404 | BLCA | Male-baised eQTL |
| rs7200095 | chr16:25376338:A:G | - | -0.0526680618256501 | 0.0372214871454578 | BLCA | Male-baised eQTL |
| rs7187099 | chr16:25380692:T:C | - | -0.0522209335168044 | 0.0401692769582661 | BLCA | Male-baised eQTL |
| rs2023659 | chr16:25377360:G:A | - | -0.052148357778564 | 0.0411905004660959 | BLCA | Male-baised eQTL |
| rs7198142 | chr16:25379353:T:C | - | -0.051829001836063 | 0.0433183193178407 | BLCA | Male-baised eQTL |
| rs13336805 | chr16:25334600:G:A | - | -0.0583097511933886 | 0.0454753577745283 | BLCA | Male-baised eQTL |
| rs8051732 | chr16:25372978:T:C | - | -0.0517257273764348 | 0.0465934145267573 | BLCA | Male-baised eQTL |
| rs11640462 | chr16:20457486:C:T | - | 0.0487595240954938 | 0.0479142639026005 | BLCA | Male-baised eQTL |
| rs182021805 | chr16:24868455:C:T | - | 0.118563637867515 | 0.00362997039303957 | LUAD | Male-baised eQTL |
| rs11643556 | chr16:25067017:G:C | - | 0.123506832176354 | 0.00703414243492065 | COAD | Male-baised eQTL |
| rs9925928 | chr16:24319336:T:C | - | -0.0643362876623492 | 0.0196678991867594 | COAD | Male-baised eQTL |
| rs7201623 | chr16:24319591:C:T | - | -0.0643362876623492 | 0.0196678991867594 | COAD | Male-baised eQTL |
| rs9929091 | chr16:25066957:G:C | - | 0.106302024919321 | 0.0247976090102569 | COAD | Male-baised eQTL |
| rs9925729 | chr16:24319068:T:A | - | -0.0601495462049349 | 0.0351052311487851 | COAD | Male-baised eQTL |
| rs9933728 | chr16:28245477:G:T | - | -0.0555041775240151 | 0.035857528547472 | COAD | Male-baised eQTL |
| rs7498538 | chr16:25074616:A:G | - | 0.0969293026474082 | 0.0391653340753988 | COAD | Male-baised eQTL |
| rs28593217 | chr16:28244378:G:A | - | 0.0579779492147748 | 0.0467276680835025 | COAD | Male-baised eQTL |
| rs17639827 | chr16:28255287:G:T | - | -0.0564530611253699 | 0.0474434092515993 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000184730 |
| CpG Site: cg16332159 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.440292908891997 | |
 | Gene ID: ENSG00000184730 |
| CpG Site: cg07337290 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.24107246375272 | |
 | Gene ID: ENSG00000184730 |
| CpG Site: cg07337290 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.419725451901094 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg16332159 | chr16:28494638 | promoter | -0.440292908891997 | 6.77081693165413e-15 | -0.5132449154770747 | 1.5426992010130282e-18 | LUAD |
| cg07337290 | chr16:28493999 | promoter | -0.24107246375272 | 5.27825301363668e-08 | -0.400733971147499 | 2.9613015912269086e-11 | LUAD |
| cg07337290 | chr16:28493999 | promoter | -0.419725451901094 | 8.82408232666074e-07 | -0.5252554766439058 | 6.196852142525704e-10 | LIHC |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of APOBR |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
